Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group
Makaleler > Tam Makale · 2025
Yazarlar: SALİH TÜNBEKİCİ, GÖKHAN ŞAHİN, Sercan ÖN, AHMET ORUÇ, MELEK KARAKURT ERYILMAZ, ABDULLAH SAKİN, ALPER COŞKUN, MUSTAFA SEYYAR, FATMA KESKİN UZUNDERE, erdem kölemen, DEVRİM ÇABUK, SAFA CAN EFİL, TEYFİK DEMİR, EMİNE TÜRKMEN, FERHAT EKİNCİ, AYTAÇ TERZİ, TAHA KORAY ŞAHİN, DENİZ CAN GÜVEN, SERCAN AKSOY, ALİ AYTAÇ, ÖZGE DEMİRKIRAN, BİLGİN DEMİR, İsmet Çulcuoğlu, MUSTAFA ERSOY, ESRA ASARKAYA, UFUK ÇAMANLI, Barış GEZİCİ, AHMET ÖZVEREN, ALPER SEVİNÇ, SAİT KİTAPLI, AHMET ÜNLÜ, BANU ÖZTÜRK, ALPER TÜRKEL, MUTLU DOĞAN, FERİT ASLAN, ENES YEŞİLBAŞ, ESMANUR KAPLAN, TEOMAN ŞAKALAR, ELİF ŞAHİN, GAMZE EMİN, ESRA AŞIK, Atilla Yıldırım, TALİHA GÜÇLÜ KANTAR, İrem Uğurlu, Fatma Kahvecioğlu, İLHAN HACIBEKİROĞLU, İbrahim Tünbekici, SELAMİ BAYRAM, ALİ OSMAN KAYA, NARGIZ MAJIDOVA, ÖZGE YALICI, MURAT KARATEKE, NİLÜFER AVCI, BURCU BELEN AYDOĞMUŞ, Hamit Bal, OĞUZCAN KINIKOĞLU, FATMA PAKSOY TÜRKÖZ, EDA TANRIKULU ŞİMŞEK, Oğuz Altınok, TUĞÇE KÜBRA GÜNEŞ, YUNUS EMRE ALTINTAŞ, MURAD GULIYEV, GÖKHAN ÖZTÜRK, DİLEK ERDEM, YAKUP DÜZKÖPRÜ, ALİ İNAL, AliKaan Gürel, NİLGÜN YILDIRIM, TUĞBA AKIN TELLİ, YURDAGÜL DANACI, UMUT AYDIN, ELVINA ALMURADOVA, HASAN ÇAĞRI YILDIRIM, Pınar GÜRSOY, MEHMET ALİ NAHİT ŞENDUR, Erdem GÖKER
International Journal of Cancer, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2025, cilt 158, ss 1881-1890
DOI: 10.1002/ijc.70213
Özet
Sacituzumab govitecan (SG) is an antibody-drug conjugate approved for metastatic or unresectable locally advanced triple-negative breast cancer (mTNBC) after at least two prior systemic therapies, yet real-world evidence remains limited. We conducted a retrospective, multicenter study including 285 patients with unresectable locally advanced or metastatic TNBC treated with SG across 52 oncology centers in Turkey. Median progression-free and overall survival were 5.4 months (95% confidence interval [CI], 4.6-6.2) and 12.2 months (95% CI, 10.5-13.9), respectively, with a 12-month overall survival rate of 49.2%. The objective response rate and disease control rate in evaluable patients were 36.8% and 63.9%. Grades 3-4 adverse events, mainly neutropenia, occurred in 44.2% of patients. Dose reductions were needed in 20% of cases; no treatment-related deaths were reported. Our large real-world cohort reinforces the effectiveness and manageable safety profile of SG, mirroring pivotal trials, and highlights its value as a therapeutic option in diverse and heavily pretreated mTNBC populations.